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Abstract
Published reports in 2006 on systemic lupus erythematosus are
reviewed with regard to preclinical and clinical studies on
disturbances of the immune system including co-stimulation,
cytokines and recent insights into new therapeutic approaches.
Increasing knowledge of components of the innate immune
system, such as certain receptors (Toll-like receptors, Fc receptors
and complement receptors) and cytokines as well as immune cells
(dendritic cells, plasmacytoid cells and neutrophils) supports their
immunopathogenic relevance and enhance our understanding of
the pathogenic complexity of lupus. Although it remains to be
shown which of those could be targets for therapy or biomarkers,
lymphocyte-directed therapy is currently under promising clinical
investigation.
Introduction
It is always tempting to look at what has been achieved
during a year and evaluate the speed, quality and extent of
research data in systemic lupus erythematosus (SLE).
Although it will be impossible to determine the impact of
these new data, we will try to critically review relevant
published peer-reviewed research of the year 2006. Because
there were several data directly or indirectly linked to
mechanisms of innate immunity, we will highlight these
aspects because it will help our understanding of activated
cells in systemic inflammation beyond interactions between T
and B lymphocytes.
There is an increasing number of potential new immuno-
therapeutic agents under investigation, such as monoclonal
antibodies directed toward lymphocyte surface antigens and
co-stimulatory signals, cytokines and modulatory agents of
immune receptors. It is apparent that the recognition of unmet
medical needs of severely ill patients with SLE and of
research in the field of immunology has begun to translate
into innovative drugs for improved treatments for patients.
This review is separated into specific categories: preclinical
studies in lupus mice, clinical studies on immunopatho-
genesis, genetics, environmental factors and biomarkers, and
finally therapy.
Preclinical studies in murine lupus
SLE is a typical autoimmune disorder and has been
considered to result from disturbed tolerance to self-antigens.
Although many cell types apparently contribute to auto-
immune disorders, lymphocytes are considered to be key
effector cells in the initiation, propagation and maintenance of
specific autoimmunity. During normal lymphopoiesis, few self-
reactive B lymphocytes emerge [1]. B-cell-activating factor
(BAFF) is an important B-cell survival factor [2] produced by
myeloid cells, T cells and different stromal cells [3]. This
member of the TNF superfamily acts via three distinct BAFF
receptors: B-cell maturation protein (BCMA), transmembrane
activator and calcium modulator ligand interactor (TACI) and
BAFF receptor (BAFF-R). Mice overexpressing BAFF develop
SLE/Sjögren’s-like autoimmunity [4]. Because BAFF is
triggering two distinct NF-κB-signalling pathways (the
classical and alternative NF-κB pathways), a recent study [5]
was able to dissect which NF-κB pathway and which B-cell
subsets are involved in developing autoimmunity, by using
BAFF-Tg mice and other genetically engineered mice.
Interestingly, they found that CD40-dependent germinal
center (GC) formation was not required for the development
of SLE-like disease. In contrast, another splenic B-cell
compartment, the marginal zone (MZ), was found to be
enlarged in BAFF-Tg mice. In these MZ cells, survival
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depended mainly on the alternative NF-κB pathway and
contained the majority of autoreactive B cells. The study
showed in particular that the alternative NF-κB pathway is
indispensable for enhanced survival of peripheral B cells and
for the manifestation of SLE in BAFF-Tg mice. SLE
development in BAFF-Tg mice was clearly dependent on
both NF-κB pathways. The interesting finding that neither
CD40-mediated interactions between B cells and T cells nor
GC formation had an important role in lupus pathogenesis of
BAFF-Tg mice indicates a substantial role of innate immunity
as well as T-cell-independent activation of B cells [6]. It will
be interesting to see to what extent other pathways resulting
in classical or alternative NF-κB activation can also influence
B-cell survival as well as B-cell functions, and whether
blocking certain pathways will provide an efficacy outranging
toxicity. Nevertheless, the identification of the source of
enhanced BAFF production in SLE and its regulation remains
open. This may provide additional clues about the role of
‘innate compartments’ in lupus.
Another study [7] analyzed the potential of targeting BAFF
and its homologue APRIL (‘A proliferation-inducing ligand’) as
therapeutic targets. The authors studied the effects of BAFF
receptor–immunoglobulin, which blocks only BAFF, with
those of TACI–immunoglobulin, inhibiting both BAFF and
APRIL, in an NZB/NZW mouse model. Both reagents led to
prolonged survival of NZB/NZW F1 mice when administered
either before or after disease onset. These treatments
showed comparable B-cell subset depletion and prevention
of T-cell activation as well as dendritic cell accumulation
without substantial effects on the emergence of the IgG anti-
double-stranded DNA response. Blockage of both BAFF and
APRIL, but not that of BAFF alone, reduced the serum levels
of IgM antibodies and the frequency of plasma cells, and
inhibited the IgM response to a T-cell-dependent antigen.
Although the antagonism of BAFF and APRIL is a promising
therapeutic approach for B-cell-mediated autoimmunity, it still
is not quite clear whether blockage of survival factors is
sufficient to inhibit immune reactions significantly. However,
an important result of that study was the confirmation of the
dominant role of BAFF/BAFF-R interactions for the survival of
MZ and follicular B cells in these mice. From our perspective,
this study also suggests that selective targeting of MZ cells
seems to be very challenging by a blockage of BAFF and/or
APRIL.
The development of B cells and their control mechanism and
pathways remain subjects of great interest. Despite apparent
intrinsic abnormalities, the influence of 17β-estradiol has
been analyzed in detail in BALB/c mice [8]. It is noteworthy
that this factor, previously known to induce lupus, was found
to enhance the maturation of pathogenic naive B cells,
whereas the development of a protective B-cell repertoire
was disturbed. In particular, this study has shown that an
important check point of selection during B-cell transition
was impaired at high dosages of this estrogen. This report is
consistent with other studies indicating that at earlier stages
of B-cell development (pre-GC stages), autoreactive B cells
can already emerge and circumvent negative selection. This
expands previous hypotheses that most autoreactive cells are
generated in the GC with a subsequent lack of appropriate
negative selection.
Several reports have identified soluble factors with the
potential to influence disease outcome; one of these is
hepatocyte growth factor, which is able to prevent lupus
nephritis, autoimmune sialadenitis and autoimmune cholangitis
[9]. The mechanism of action of hepatocyte growth factor is
considered to inhibit Th2 cell functions. Another promising
approach is blockage of IL-6 [10-12] initially identified as B-
cell growth factor, as well as modulating Toll-like receptor
(TLR) signalling by oligomers [13]. IL-6 targeting seems to be
unique because data indicate its clinical value in rheumatoid
arthritis and SLE, which has not been seen for other
biological agents.
Considerable progress has been reported in the field of
TLRs. The potential of activating innate immunity by TLR-9
agonists that recognize bacterial DNA has been
demonstrated in a genetically predisposed mouse (MRL
lpr/lpr) [14], triggering the onset of lupus nephritis. In these
mice, CpG DNA, a specific agonist for TLR-9 but –
surprisingly – no other ligands of TLR-3 or TLR-7, was able to
induce lupus in this strain. Both TLR-7 and TLR-9 are
expressed by B lymphocytes, a critical feature for the
induction of nucleic-acid-specific autoantibodies. Pawar and
colleagues [14] found that only CpG DNA induced sufficient
B lymphocyte proliferation and anti-double-stranded DNA
(dsDNA) IgG2a production. In contrast with the findings of
this study [14], TLR-9 has been found on a C57BL/6
background to protect against the development of lupus
nephritis [15]. However, a spontaneous model [16] using the
same strain for TLR-7 or TLR-9 knockout mice provided
evidence that TLR-7 is protective. The titer of anti-dsDNA
autoantibodies was strikingly higher in TLR-9–/– mice. It is
important to note that Pawar and colleagues [14] used an
exogenous agonist to activate TLR-9, whereas previous
studies used endogenous agonists of TLR-9. Interestingly,
the current data support the notion that TLRs have different
functions in autoimmunity and are not themselves promoting
autoimmunity. Thus, TLR-7 recognizing single-stranded RNA
promotes autoimmune disease, whereas TLR-9 recognizing
DNA was found to protect against lupus-like disease in mice
[16]. Although TLR-9 can induce the secretion of anti-
chromatin autoantibodies, there is clear evidence that the
TLRs have regulatory functions involving B cells, T cells,
dendritic cells (DCs) and soluble mediators that are by far
more complex than initially thought and need further
exploration. However, TLR-9 function represents an example
that autoantibody production and the development of a
systemic autoimmunity do not essentially overlap. This is
supported by clinical observations in some patients.Page 3 of 10
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Other recently published studies support a role for TLR-7 as
a receptor for RNA in the generation of autoantibodies and
lupus nephritis [17]. In this context, the Y-chromosome-linked
autoimmune accelerating (yaa) locus has been mapped to a
translocation and duplication of the TLR-7 locus, indicating
that gene dosage and expression of TLR-7 also can contri-
bute to SLE [18,19]. The identification of this gene duplica-
tion with its functional consequences is one of the most
important recent achievements, but its clinical impact on
human disease needs more investigation.
Ehlers and colleagues [20] further studied downstream effects
of the TLR-9–MyD88 pathway in detail and found that its
signalling is required for the generation of pathogenic anti-
DNA/polyreactive IgG2a and IgG2b autoantibodies. These
subclasses efficiently trigger inflammatory responses by their
ability to preferentially engage the activation receptor FcγRIV
on macrophages [21]. An important observation of these
experiments was that TLR-9–MyD88 signalling is able to
promote class switching. Moreover, IgG2a and IgG2b seemed
to be important pathogenic agents to activate macrophages
because a lack of TLR-9, IgG2a and IgG2b autoantibodies led
to a similar reduction of autoimmunity to that found in MyD88-
deficient mice. Although the data are very compelling, the role
of TLR-9 in lupus autoimmunity is considered rather protective
against lupus (see above), and involvement of other TLRs
and/or complement receptors cannot be ruled out.
In another report [22] the implications of TLRs were analyzed
using purified nucleosomes, which are major autoantigens in
SLE. This particular study showed that physiological
concentrations of nucleosomes were endocytosed and
induced the activation of human neutrophils. As a result,
these cells upregulated CD11b/CD66b, induced IL-8 and
increased their phagocytic activity. Here nucleosomes could
induce activation of neutrophils independently of
unmethylated CpG DNA motifs and also independently of the
formation of immune complexes. Interestingly, neutrophil
activation was independent of TLR-2 and TLR-4. Although
the exact pathway has yet to be identified, activated
neutrophils are suspects for the link between innate and
adaptive immunity that results in antinucleosomal antibodies,
a characteristic feature of disturbed tolerance in SLE
patients. After years of studying T-cell and B-cell aspects in
lupus, the interesting data of this study finally support the
concept that neutrophils could have an important
inflammatory function, in particular in final tissue destruction.
In summary of this section, there is increasing literature on the
role of TLRs, especially TLR-7 and TLR-9, with some
conflicting data. Thus, the role of TLRs in lupus autoimmunity
remains to be elucidated. Given that most data were obtained
on selected inbred strains of mice that have unique pheno-
types and requirements for disease development, under-
standing human lupus is even more challenging. Another
important aspect is that the nature of TLR ligands determines
whether an oligomer is activating or inhibitory. This quality
can be changed by very subtle modifications and needs to be
considered in the interpretation of studies.
Despite the studies on macrophages [20] and neutrophils
[22] as compartments of innate immunity, DCs are the
subject of intensive research, and a large body of evidence
supports their central role in lupus pathogenesis. In that
context, Colonna and colleagues [23] analyzed the pheno-
type of dendritic cells in different backgrounds of lupus mice.
Importantly, this study identified an altered co-stimulatory
profile with significantly enhanced expression of CD40 and
decreased expression of CD80 and CD54, whereas the
expression of another member of this family, CD86, was
normal. Similar data about defective CD80 expression on
DCs have been obtained by previous studies on patients with
lupus. Interestingly, and in contrast with available data in
patients with SLE, the study identified an overexpression of
CD40 before disease onset. This indicates that DCs in these
mice are prone to escape from tolerance and have a key role
in very early immune activation.
The role in lupus of type I IFN, in particular IFN-α, which is a
candidate as a key cytokine in lupus, has been further
explored. The emergence of lupus-like disease in patients
treated with IFN-α has been reported [24,25] and resolved
on discontinuation of treatment with IFN-α. Rönnblom and
colleagues [26] first identified the involvement of this cytokine
in SLE. However, a study in MRL mice by Hron and Peng
[27] showed that IFN-RII protected against the development
of lupus, but IFN-RI-deficient mice worsened
lymphoproliferation and organ damage. Similarly, studies by Li
and colleagues [28] analyzed the effects of IFN-I and
blockage of IFN-I in B6.Sle2 mice. Interestingly, treatment
with IFN-α led to an improvement in B6.Sle2 congenics,
which contradicts the notion that this cytokine has such a
central pathogenic role in lupus.
Recently, Feng and colleagues [29] analyzed five type I IFN-
inducible genes (LY6E, OAS1, OASL, MX1 and ISG15) in 48
patients with SLE, 48 normal controls and 22 patients with
other rheumatic diseases (14 patients with rheumatoid arthritis
and 8 patients with Wegener’s granulomatosis) for their
mRNA expression levels. All genes were highly and uniquely
expressed in patients with SLE, compared with all controls.
Moreover, SELENA/SLEDAI scores and the physician’s global
assessment score were correlated with the expression levels
and confirmed previous experiences that glucocorticoids can
downregulate the expression of IFN-inducible genes. Notably,
patients with lupus nephritis and flaring had higher IFN-
inducible gene expression. One particular gene, LY6E,
showed a correlation of its levels with lupus nephritis and was
suggested as biomarker for lupus nephritis.
However, IFN-α was also found at enhanced levels in patients
with rheumatoid arthritis, Sjögren’s syndrome [30] and
Available online http://arthritis-research.com/content/9/4/215dermatomyositis [31], as well as in unaffected relatives of
lupus patients. Therefore, the ‘IFN signature’ is apparently not
uniquely linked to SLE. The role of IFN-α and its receptor will
remain of central interest in lupus but requires additional
exploration.
IFN-α is produced mainly by plasmacytoid dendritic cells
(pDCs), which have been found at reduced frequencies in the
blood of patients with SLE but are likely to reside in the
tissues [26,32,33]. It is noteworthy that TLR-7 and TLR-9
seem to be involved in pDC activation and can induce the
production of IFN-α [34]. Currently, it is suggested that
activation of TLRs remains an early event and results in the
activation of innate and adaptive immunity, with IFN-α being
the key cytokine. Why lupus patients respond so differently,
namely with enhanced IFN-α production compared with
controls, remains unclear. Although the IFN signature in lupus
seems to be related to pDC activation by TLR-7 or TLR-9
agonists, it remains to be determined whether pDCs initiate
or amplify the pathogenic circle.
‘From bench to bedside’ has gained new data in 2006,
especially giving insight into innate autoimmunity. It will be
interesting to see how, and to what extent, immuno-
modulation of blocking specific receptors or ligand–ligand
interactions, targeting of cellular compartments, and soluble
or insoluble factors of immune activation will translate into
future clinical practice.
Discoveries on genetics, environmental
factors and biomarkers
Genetics: relatively stable differences
Because the induction of human SLE is clearly dependent on
an interplay between hereditary factors and exposure to
environmental agents, it is crucial to identify underlying genes
of lupus susceptibility. Studies in mice [35] explored the
possibility that the presence of Sle1z/Sle1z within the
susceptibility locus is important for B-cell regulation, includ-
ing the gene Ly108.1. Ly108.1 was highly expressed on
immature B cells of B6.Sle1z mice candidates as a critical
censor of self-reactive B cells.
Graham and colleagues [36] identified a common haplotype
of the interferon regulatory factor 5 (IRF5) gene that regulates
mRNA splicing and the expression of IFN-α and was strikingly
associated with SLE. This replicate study showed the
association of the IRF5 rs2004640 T allele and SLE in four
case-control cohorts and family-based transmission disequili-
brium test analysis. If more functional data can be obtained
after this association, the pathogenic impact of type I IFN may
become more robust and may help to overcome some
contradictions as noted above.
A recent review [37] summarized certain genes identified
within different pathways and immune compartments that all
contribute to the induction of specific autoantibodies and
pathogenic autoimmunity, finally leading to end organ
damage. A meta-analysis of genome-wide linkage studies in
patients with SLE [38] summarized putative susceptibility loci
for SLE by independent studies. Suggestive regions on
6p21.1–q15, 20p11–q13.13 and 16p13–q12.2 represent
the highest relation to the disease, with the region on
chromosome 6 containing HLA. It remains an open question
whether this class II susceptibility is more related to
autoantibody production or to the disease itself.
Another genetic variable for the course of the disease is the
relation to gene polymorphisms and the response to specific
drugs, as is known for cytotoxic drugs in oncology. A study by
Lopez and colleagues [39] provided evidence that the clinical
efficacy of antimalarial drugs depends on polymorphisms of
the cytokines TNF-α and IL-10. The combined genotype of
high producers of TNF-α and low producers of IL-10
responded  better to antimalarial treatment and had milder
disease courses among the 192 patients studied. This study
may be just the beginning of a complex analysis in which
certain polymorphisms of several variables need to be
considered for the dissection of unique characteristics of the
disease from individual profiles. These profiles have the
potential to result in patient-tailored therapies, which becomes
more important when the therapeutic possibilities enlarge.
Environmental factors
Despite the known role of ultraviolet exposure and estrogens,
from our perspective two aspects need particular emphasis in
2006. First of all, smoking [40-42] is clearly documented as a
risk factor for SLE and the production of anti-dsDNA
antibodies. The interaction of smoking as environmental
factor with underlying genetic predispositions for immune
activation is known for SLE, rheumatoid arthritis (RA) and
ulcerative colitis, whereas the presence of HLA-DRB1SE is a
cofactor in RA, and HLA-DR3 and IRF5 [36] represent risk
factors for anti-DNA production in SLE.
Discoveries of immunopathogenesis
SLE as a classic autoimmune disease has multiple facets of
disturbances of the immune system, and the search to
identify additional abnormalities continues.
Regulation of the immune system follows an interplay between
molecules and their receptors by balancing activation and
inhibition in a timely manner. Among important regulating
receptors, Fc receptors largely expressed on very different
cells have attracted great interest, particularly the unique
inhibitory FcγRIIB. After demonstrating its importance in
mouse models, Mackay and colleagues [43] analyzed the
expression of FcγRIIB in human SLE and found that
upregulation of FcγRIIB was significantly decreased in
memory B cells of patients with SLE. Notably, some African-
American patients failed to upregulate FcγRIIB, which is
consistent with the known higher susceptibility of severe SLE
in those patients. It is not quite clear which (genetic) factor or
Arthritis Research & Therapy    Vol 9 No 4 Hansen et al.
Page 4 of 10
(page number not for citation purposes)distinct regulatory mechanism leads to these functional
differences in FcγRIIB regulation. The data from this study,
however, support the notion that FcγRIIB is a prime candidate
for the regulation of B-cell check points involved in
susceptibility to lupus.
A recent Dutch study [44] studied the prevalence and course
of anti-chromatin antibodies (anti-nucleosome, anti-dsDNA
and anti-histone) and anti-C1q autoantibodies in 52 patients
with proliferative lupus nephritis who were enrolled in a
randomized controlled trial with either cyclophosphamide or
azathioprine plus methylprednisolone. Patients with higher
SLEDAI had higher levels of anti-nucleosome autoantibodies,
anti-C1q autoantibodies and serum creatinine. A comparable
rapid decline of anti-nucleosome, anti-dsDNA and anti-C1q
autoantibodies was seen in both treatment arms. Renal flares
were not preceded by rises in autoantibody titres. The
authors found that measurement of anti-chromatin and anti-
C1q autoantibodies is useful for diagnosing lupus nephritis.
However, these antibodies did not reliably allow monitoring
the disease course and did not seem to be a useful
biomarker; this remains a matter of debate [45].
Studies on autoimmune T and B cells
Analysis of T-cell abnormalities in SLE has been expanded by
the identification of the spliceosomal autoantigen hetero-
geneous nuclear ribonucleoprotein (hnRNP)-A2 as a major
T-cell autoantigen [46] with the use of T-cell clones. A large
number of CD8+ T-cell clones not expressing CD28 showed
anti-hnRNP-A2 reactivity despite the large number of
autoreactive CD4+ clones. The value of CD8+ T cells in SLE
autoimmunity and the capability of CD8+ cells for antigen
presentation remain less understood.
Co-stimulation by a member of the CD28 family, the inducible
co-stimulator (ICOS), has been reported in patients with
lupus [47]. By using a different antibody for detection, the
study confirmed the enhanced expression of ICOS on CD4+
and CD8+ T cells in patients with SLE compared with normal
controls, as reported previously [48]. Moreover, the
humanized antibody used (JTA009) led to enhanced
production of IFN-γ, IL-4 and IL-10 both in T cells from normal
controls and in those from lupus patients; it was also able to
induce immunoglobulin and anti-DNA antibody production in
co-cultures with B cells. Thus, blocking interaction between
ICOS and ICOS ligand is a potential candidate for
therapeutic intervention that has already been shown to be
effective in mice [49].
Of recent interest, checkpoints of B-cell development have
been studied by studying re-expressed immunoglobulin
receptors obtained from normal controls and from lupus
patients. In this regard, Wardemann and colleagues [1] found
that most early immature B cells were self-reactive,
suggesting inefficient checkpoint regulation in lupus. The
same group reported that patients with SLE in clinical
remission continue to produce elevated numbers of self-
reactive and polyreactive antibodies in the mature naive B-cell
compartment. Although the frequency of B cells expressing
autoreactive immunoglobulin was lower than during active
disease, the data suggest that early checkpoint abnormalities
are an integral feature of SLE [50].
Cardiovascular risk and SLE
Patients with SLE have a disease-related enhanced risk for
the development of cardiovascular complications. As a result,
accelerated atherosclerosis is a major cause of mortality and
morbidity in SLE, with 6 to 10% of patients developing
premature clinical coronary heart disease. In 2006, increased
intima-media thickness, an easy test in clinical practice was
confirmed to be associated with age, systolic blood pressure,
disease duration and a systematic coronary risk evaluation
[51]. Importantly, interaction between endothelial cell
activation, vascular remodeling, lipid profiles and enhanced
blood pressure and interaction with thrombocyte activation
are all critical factors and have yet to be elucidated for early
intervention to prevent cardiovascular complications.
Another cardiovascular study in SLE analyzed 200 patients
[52] and demonstrated that high titers of IgG anticardiolipin
antibodies (more than 80 IU/ml) were associated with the
development of mitral valve nodules and significant mitral
regurgitation but were not related to systolic dysfunction or
signs of atherosclerosis or myocardial hypertrophy. Because of
enhanced levels of vascular cell adhesion molecule (VCAM)-1
and TNF receptors, a mechanistic relationship between local
endothelial cell activation and TNF receptors was concluded.
This is of interest because it follows a proposed separation of
distinct endothelial cell subsets and may explain why vascular
lesions have preferred sites; that is, where characteristic
arthritis manifests itself. This was supported by recent animal
studies [53] demonstrating that local endothelium defines
where arthritic lesions develop. These data have methodo-
logical implications because results on epithelial cells are
widely derived from umbilical vein endothelial cells that may not
allow the acquisition of reliable data.
Transforming growth factor (TGF)-β β1
TGF-β1 is a potential factor involved in the balance of the
immune system and atherosclerosis. It is also considered to
be a potent naturally occurring immunosuppressant produced
by all immune cells and has a fundamental role in controlling
proliferation and the fate of cells through apoptosis. TGF-β1
in the vascular wall functions to maintain the normal vascular
wall structure; it controls the balance between inflammation
and extracellular matrix deposition in atherosclerosis and
inhibits smooth muscle and endothelial cell proliferation.
Because impairment in the TGF-β1 pathway has been
associated with both an SLE-like illness and enhanced
atherogenesis, a recent study [54] measured the efficiency of
TGF-β1 activation in SLE: patients with SLE had low to
normal TGF-β1 activation and were linked with increased
Available online http://arthritis-research.com/content/9/4/215
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duration, low-density lipoprotein levels and increased carotid
intima-media thickness. Inappropriate TGF-β1 activation in
SLE may therefore lead to disturbances of immune tolerance
and enhanced atherosclerosis, which connect vascular
biology and the immune system.
New advances in treating lupus
After the demonstration that mycophenolate mofetil is more
effective than intravenous cyclophosphamide in inducing
remission in a 24-week non-inferiority trial [55], its use for the
induction and maintenance of lupus nephritis has been shown
in larger databases [56] and provides advantages in safety.
The search for other innovative treatment options comprises
several promising compounds that are under investigation
and have been nicely summarized recently [57,58]; these
include B-cell tolerogens (LJP394), anti-B-cell-directed
antibodies (CD20 and CD22), cytokine blockage in SLE
(anti-IL-10, anti-TNF-α, anti-BAFF and anti-IL-6), anti-C5,
cytotoxic T lymphocyte-associated antigen 4 immunoglobulin
for co-stimulator blockage, and TV4710 as a DNA antibody
neutralizing agent as well as autologous stem cell transplan-
tation. Considerably more drugs are in early developmental
stages.
Additional progress has been achieved in B-cell-targeted
therapies. SLE is widely accepted as a disease of B cells,
with a plethora of autoantibodies as a hallmark of this entity.
On the surface of B cells, the B-cell receptor, as part of the
adaptive immune system, is expressed and linked with several
other extracellular and intracellular receptors of innate
immunity, such as TLRs, Fc receptors and complement
receptors. B cells are therefore a common denominator of
pathways of both the innate and adaptive immune systems,
which is impressively unique [6,59].
Data on Lymphostat B, a human monoclonal antibody that
blocks the bioactivity of BAFF or B lymphocyte stimulator
(BLys), have been reported, including its effect on B-cell
depletion of blood and tissue B cells in cynomolgus monkeys
[60,61]. The safety profile, including a lack of treatment-
related infections in animals repeatedly treated and followed
for 34 weeks after treatment, is considered favorable.
Publications of clinical trials on the use of this drug in RA and
lupus patients are awaited.
After early experiences of using B-cell depletion with anti-
CD20 (rituximab) combined with intravenous cyclophos-
phamide in otherwise refractory patients, colleagues from
University College London reported seven patients who had
relapsed and subsequently received repeated cycles of this
combination (up to three cycles) since 2000 [62]. In this first
study of repeated B-cell depletion in lupus, there was a
consistent decrease in disease activity measured by the
British Isles Lupus Assessment Group (BILAG) scoring in
consecutive treatment cycles with a mean duration of B-cell
depletion of 6 months (range 5 to 7), which is lower than that
in RA (7 months; range 6 to 8). Interestingly, the duration of
clinical benefit was frequently longer than the period of B-cell
depletion. With the exception of one patient with mild serum
sickness, re-treatment was safe, especially taking into
account the disease severity of those patients.
It is noteworthy that data are accumulating to show that
rituximab treatment in lupus nephritis may provide a promising
new agent, although data from randomized clinical trials are
awaited. Though rituximab induces important depletion of B
cells in almost all patients with SLE, it has been described
that therapy with rituximab led to changes in titers of serum
autoantibodies but had no significant effect on plasma
immunoglobulin levels. This is consistent with the concept of
different lifetimes of distinct plasma cell subsets [63].
One study found that patients with SLE receiving this
biological agent showed a diminished expression of the co-
stimulatory molecules CD40 and CD80 by B cells [64]. In
another open clinical trial [65], 22 patients with active SLE
and lupus nephritis (mainly WHO classes III and IV) were
studied; a significant reduction in disease activity and
reduced proteinuria at days 60 and 90 after rituximab therapy
were found. In 20 of 22 patients, B-cell depletion was
observed. One patient died at day 70 with invasive histo-
plasmosis. No other important adverse effects of this therapy
were registered. Significant enhancement in the levels of
different CD4+ regulatory cells (Treg, Th3 and Tr1), but not
CD8+ T lymphocytes, was seen at day 30. This increase was
sustained for Treg cells at day 90, and increased apoptosis of
T cells was seen at day 30. These observations provide
indirect evidence that B and T cells cross-talk continuously
and this can apparently not be completely replaced by any
other immune cell type.
Other immunological studies of lupus patients under B-cell
depletion therapy [66] revealed that antinucleosome anti-
bodies and anti-dsDNA antibodies decline significantly after
B-cell depletion for 6 to 8 months, with clinical improvement
in all 16 patients enrolled. Although this needs to be
confirmed with more data, it was the first study in SLE
demonstrating that antimicrobial immunity (anti-tetanus toxoid
and anti-pneumococcal antibodies) remained unchanged,
whereas 9G4+ antibodies encoding anti-DNA reactivity
declined under B-cell depletion and increased before lupus
flares. 9G4 is an interesting biomarker, but because not all
patients with SLE produce this idiotype, its wider usage in
clinical practice is prevented.
Follow-up of BAFF and APRIL levels in patients with SLE
(n = 10) and RA (n = 9) treated with rituximab provided some
very interesting distinctions between these entities under
B-cell depletion [67]. Whereas BAFF increased in both
patient groups, it decreased after B-cell repopulation. APRIL
Arthritis Research & Therapy    Vol 9 No 4 Hansen et al.
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decreased significantly under B-cell depletion. Patients with
RA had a 10-fold higher APRIL level at baseline, which did
not change under therapy with rituximab. If these data are
confirmed, our understanding of the role of BAFF, APRIL and
B cells in RA versus SLE will be enhanced.
A recent report [68] analyzed BAFF/Blys isoforms and mRNA
level in samples from 60 patients with SLE, 60 patients with
RA and 30 controls. Although there was no robust correlation
between BlyS/BAFF protein levels and disease activity, full-
length and ∆BLyS/BAFF mRNA were elevated in SLE, and
this was correlated with disease activity. Further studies will
be required to determine whether this molecule is useful as
biomarker.
Despite these encouraging data on B-cell depletion with
rituximab in SLE, including lupus nephritis and neuro-
psychiatric SLE, two deaths of patients with SLE were
reported who developed progressive multifocal leukencepha-
lopathy (PML) [69]. It has been estimated that about 10,000
patients with SLE have been exposed to rituximab. Further
careful clinical recording will be needed to evaluate the actual
risk for PML, because the development of PML might also be
related to the underlying disease itself.
One study has chosen a different pathway for targeting
B cells and has conducted an open phase IIa trial using a
humanized anti-CD22 antibody targeting mature B cells [70]
after it had been studied in patients with B-cell non-Hodgkin’s
lymphoma. The mechanism of action of this antibody is
different from that of rituximab because only about 30% of
peripheral B cells are depleted under this agent and its
activity seems to be through the negative regulation of B-cell
receptor signalling, the strongest B-cell activation signal [71].
This open clinical trial included 14 moderately active (BILAG
score 6 to 12) patients using 360 mg/m2 epratuzumab
intravenously every 2 weeks for a total of four doses. The
BILAG scores decreased by at least 50% in all 14 patients at
some point during the study; 92% of patients showed
decreases until 18 weeks, at which time 38% showed a
decrease of at least 50%. Almost all patients (93%)
experienced improvements in at least one BILAG B-level or
C-level disease activity at 6, 10 and 18 weeks. On the basis
of these data, multicenter controlled studies have been
initiated to test the value of anti-CD22 strategies.
With regard to lupus flare management, two major studies
were reported [45,72]. The use of hormones, in particular
oral contraceptives, is of continuous and great interest in
SLE. There are concerns about potential negative side
effects, especially inducing lupus flare. A double-blind,
randomized, non-inferiority trial [72] evaluated the effect of
oral contraceptives on lupus activity in 183 premenopausal
lupus patients receiving either oral contraceptives (triphasic
ethynyl estradiol plus norethindrone) or placebo over a 12-
month period with the primary endpoint of a severe lupus
flare. These flares were reported in 7.7% of patients
receiving oral contraceptives compared with 7.6% under
placebo, giving similar flare rates of 0.084 and 0.087,
respectively. In terms of thrombosis, the rates were not
significantly different during the observation period. Although
the study showed that oral contraceptives do not lead to
higher flare rates among women with lupus, the relatively
short observation period did not address long-term risks
such as thrombembolic event rate and enhanced risks for
breast cancer. Moreover, the study excluded patients with
lupus anticoagulant, a patient population at even greater risk
for vascular occlusions. In this group of patients, however,
we are in great need for better management; data under
long-term anticoagulation are not robust.
Another randomized placebo controlled trial led by Tseng and
colleagues [45] could identify risk factors for lupus flare
among 154 patients studied serologically by elevated C3a
levels and raised anti-dsDNA antibodies before lupus flare.
The use of short-term corticosteroid therapy at the time of
serologic flares prevented disease activation significantly,
which may fundamentally support clinical decisions. This
confirms a former study [73] showing that relapses can be
prevented by giving prednisone when an increase in anti-
dsDNA occurs.
Curative therapy might require the elimination of long-lived
plasma cells secreting pathogenic autoantibody memory
without need for restimulation. These cells are refractory to
immunosuppressive drugs and B-cell depletion. So far, the
depletion of these cells has been achieved by complete
immunoablation in combination with autologous stem cell
transplantation. The development of novel approaches for
specific elimination of autoreactive plasma cell memory
remains a challenge for the future [74,75].
From a very different perspective, new drugs and regimens
teach us continually about underlying mechanisms of auto-
immunity. In this regard, we have learned that graft-versus-
host immunity can induce scleroderma and Sjögren-like
diseases. Most recently, Burt’s group reported the develop-
ment of a secondary autoimmune disorder after hemato-
poietic stem cell transplantation in autoimmune patients [76].
Of 155 patients transplanted, 6 developed some sort of
secondary autoimmune disorder. Two patients with SLE
developed factor VIII inhibitors, four patients (two with
multiple sclerosis, one with lupus and one with systemic
sclerosis) developed autoimmune cytopenias. This complica-
tion occurred in 15% of patients treated with alemtuzumab
(Campath, anti-CD52) and in 1.9% of patients treated with
antithymocyte globulin (ATG). There was no link with gender,
type of ATG, CD34 selection or the development of
secondary autoimmunity, in contrast with an association with
the use of alemtuzumab. Thus, anti-CD52 depletion seems to
disrupt important negative regulators of autoimmunity.
Available online http://arthritis-research.com/content/9/4/215
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involved in innate and adaptive immunity, detailed studies will
be needed to identify the underlying mechanisms of action
involved.
Conclusion
This review seeks to highlight some reports published in
2006 about lupus and is by its nature restricted. After years
of major contributions by studies of B and T lymphocytes that
led to innovative therapies in lupus, such as B-cell depletion,
blockade of co-stimulation or cytokines, there are new
insights into the pathogenic role of innate immunity. As
examples, the disputed role of TLRs, complement receptors
and Fc receptors partly expressed on neutrophils, dendritic
and plasmacytoid dendritic cells may open new fields of
lupus research and may finally change pathogenic and
therapeutic concepts.
Competing interests
TD was involved in the clinical phase IIa trial of epratuzumab
in SLE, which was sponsored by Immunomedic, Inc. The
work was supported by DFG grants (SFB421 and 650).
Acknowledgements
The authors thank Christine Raulfs for critical reading of the manu-
script.
References
1. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E,
Nussenzweig MC: Predominant autoantibody production by
early human B cell precursors. Science 2003, 301:1374-1377.
2. Batten M, Groom J, Cachero TG, Qian F, Schneider P, Tschopp J,
Browning JL, Mackay F: BAFF mediates survival of peripheral
immature B lymphocytes. J Exp Med 2000, 192:1453-1465.
3. Mackay F, Tangye SG: The role of the BAFF/APRIL system in B
cell homeostasis and lymphoid cancers. Curr Opin Pharmacol
2004, 4:347-354.
4. Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schnei-
der P, Tschopp J, Cachero TG, Batten M, Wheway J, et al.: Asso-
ciation of BAFF/BLyS overexpression and altered B cell
differentiation with Sjogren’s syndrome. J Clin Invest 2002,
109:59-68.
5. Enzler T, Bonizzi G, Silverman GJ, Otero DC, Widhopf GF,
Anzelon-Mills A, Rickert RC, Karin M: Alternative and classical
NF-κ κB signaling retain autoreactive B cells in the splenic mar-
ginal zone and result in lupus-like disease. Immunity 2006,
25:403-415.
6. Dorner T: Crossroads of B cell activation in autoimmunity:
rationale of targeting B cells. J Rheumatol 2006, 33:3-11.
7. Ramanujam M, Wang XB, Huang WQ, Liu Z, Schiffer L, Tao HO,
Frank D, Rice J, Diamond B, Yu KO, et al.: Similarities and differ-
ences between selective and nonselective BAFF blockade in
murine SLE. J Clin Invest 2006, 116:724-734.
8. Grimaldi CM, Jeganathan V, Diamond B: Hormonal regulation of
B cell development: 17 β β-estradiol impairs negative selection
of high-affinity DNA-reactive B cells at more than one devel-
opmental checkpoint. J Immunol 2006, 176:2703-2710.
9. Kuroiwa T, Iwasaki T, Imado T, Sekiguchi M, Fujimoto J, Sano H:
Hepatocyte growth factor prevents lupus nephritis in a murine
lupus model of chronic graft-versus-host disease. Arthritis Res
Ther 2006, 8:R123.
10. Kishimoto T: Interleukin-6: discovery of a pleiotropic cytokine.
Arthritis Res Ther 2006, 8(Suppl 2):S2.
11. Lipsky PE: Interleukin-6 and rheumatic diseases. Arthritis Res
Ther 2006, 8(Suppl 2):S4.
12. Nishimoto N, Kishimoto T: Interleukin 6: from bench to bedside.
Nat Clin Pract Rheumatol 2006, 2:619-626.
13. Lenert PS: Targeting toll-like receptor signaling in plasmacy-
toid dendritic cells and autoreactive B cells as a therapy for
lupus. Arthritis Res Ther 2006, 8:203.
14. Pawar RD, Patole PS, Ellwart A, Lech M, Segerer S, Schlondorff
D, Anders HJ: Ligands to nucleic acid-specific toll-like recep-
tors and the onset of lupus nephritis. J Am Soc Nephrol 2006,
17:3365-3373.
15. Lartigue A, Courville P, Auquit I, Francois A, Arnoult C, Tron F,
Gilbert D, Musette P: Role of TLR9 in anti-nucleosome and
anti-DNA antibody production in lpr mutation-induced murine
lupus. J Immunol 2006, 177:1349-1354.
16. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA,
Shlomchik MJ: Toll-like receptor 7 and TLR9 dictate autoanti-
body specificity and have opposing inflammatory and regula-
tory roles in a murine model of lupus. Immunity 2006,  25:
417-428.
17. Berland R, Fernandez L, Kari E, Han JH, Lomakin I, Akira S, Wortis
HH, Kearney JF, Ucci AA, Imanishi-Kari T: Toll-like receptor 7-
dependent loss of B cell tolerance in pathogenic autoantibody
knockin mice. Immunity 2006, 25:429-440.
18. Pisitkun P, Deane JA, Difilippantonio MJ, Tarasenko T, Satterth-
waite AB, Bolland S: Autoreactive B cell responses to RNA-
related antigens due to TLR7 gene duplication. Science 2006,
312:1669-1672.
19. Subramanian S, Tus K, Li QZ, Wang A, Tian XH, Zhou J, Liang C,
Bartov G, McDaniel LD, Zhou XJ, et al.:  A Tlr7 translocation
accelerates systemic autoimmunity in murine lupus. Proc Natl
Acad Sci USA 2006, 103:9970-9975.
20. Ehlers M, Fukuyama H, Mcgaha TL, Aderem A, Ravetch JV:
TLR9/MyD88 signaling is required for class switching to path-
ogenic IgG2a and 2b autoantibodies in SLE. J Exp Med 2006,
203:553-561.
21. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV: Fcγ γRIV: a novel
FcR with distinct IgG subclass specificity. Immunity 2005, 23:
41-51.
22. Rönnefarth VM, Erbacher AI, Lamkemeyer T, Madlung J, Nordheim
A, Rammensee HG, Decker P: TLR2/TLR4-independent neu-
trophil activation and recruitment upon endocytosis of nucleo-
somes reveals a new pathway of innate immunity in systemic
lupus erythematosus. J Immunol 2006, 177:7740-7749.
23. Colonna L, Dinnall JA, Shivers DK, Frisoni L, Caricchio R, Gallucci
S:  Abnormal costimulatory phenotype and function of den-
dritic cells before and after the onset of severe murine lupus.
Arthritis Res Ther 2006, 8:R49.
24. Niewold TB, Swedler WI: Systemic lupus erythematosus
arising during interferon-α α therapy for cryoglobulinemic vas-
culitis associated with hepatitis C. Clin Rheumatol 2005, 24:
178-181.
25. Rönnblom L, Alm GV: An etiopathogenic role for the type IIFN
system in SLE. Trends Immunol 2001, 22:427-431.
26. Rönnblom L, Alm GV: Systemic lupus erythematosus and the
type I interferon system. Arthritis Res Ther 2003, 5:68-75.
27. Hron JD, Peng SL: Type I IFN protects against murine lupus. J
Immunol 2004, 173:2134-2142.
28. Li J, Liu Y, Xie C, Zhu J, Kreska D, Morel L, Mohan C: Deficiency
of type I interferon contributes to Sle2-associated component
lupus phenotypes. Arthritis Rheum 2005, 52:3063-3072.
29. Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD,
Park GS, Dong X, Chen W, Kim MH, Weng HH, et al.: Associa-
tion of increased interferon-inducible gene expression with
disease activity and lupus nephritis in patients with systemic
lupus erythematosus. Arthritis Rheum 2006, 54:2951-2962.
30. Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S,
Lazure T, Jacques S, Ba N, Ittah M, Lepajolec C, et al.: Activation
of IFN pathways and plasmacytoid dendritic cell recruitment
in target organs of primary Sjogren’s syndrome. Proc Natl
Acad Sci USA 2006, 103:2770-2775.
31. Wenzel J, Schmidt R, Proelss J, Zahn S, Bieber T, Tuting T: Type I
interferon-associated skin recruitment of CXCR3+ lympho-
cytes in dermatomyositis. Clin Exp Dermatol 2006,  31:576-
582.
32. Båve U, Nordmark G, Lövgren T, Rönnelid J, Cajander S, Eloranta
ML, Alm GV, Rönnblom L: Activation of the type I interferon
system in primary Sjogren’s syndrome – a possible etiopath-
ogenic mechanism. Arthritis Rheum 2005, 52:1185-1195.
33. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL:
Plasmacytoid dendritic cells (natural interferon-α α/β β-producing
Arthritis Research & Therapy    Vol 9 No 4 Hansen et al.
Page 8 of 10
(page number not for citation purposes)cells) accumulate in cutaneous lupus erythematosus lesions.
Am J Pathol 2001, 159:237-243.
34. Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S,
Chang B, Duramad O, Coffman RL: Nucleic acids of mam-
malian origin can act as endogenous ligands for toll-like
receptors and may promote systemic lupus erythematosus. J
Exp Med 2005, 202:1131-1139.
35. Kumar KR, Li L, Yan M, Bhaskarabhatla M, Mobley AB, Nguyen C,
Mooney JM, Schatzle JD, Wakeland EK, Mohan C: Regulation of
B cell tolerance by the lupus susceptibility gene Ly108.
Science 2006, 312:1665-1669.
36. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM,
Bauer JW, Ortmann WA, Koeuth T, González Escribano MF;
Argentine and Spanish Collaborative Groups, et al.: A common
haplotype of interferon regulatory factor 5 (IRF5) regulates
splicing and expression and is associated with increased risk
of systemic lupus erythematosus. Nat Genet 2006,  38:550-
555.
37. Fairhurst AM, Wandstrat AE, Wakeland EK: Systemic lupus ery-
thematosus: multiple immunological phenotypes in a
complex genetic disease. Adv Immunol 2006, 92:1-69.
38. Forabosco P, Gorman JD, Cleveland C, Kelly JA, Fisher SA,
Ortmann WA, Johansson C, Johanneson B, Moser KL, Gaffney
PM, et al.: Meta-analysis of genome-wide linkage studies of
systemic lupus erythematosus. Genes Immun 2006,  7:609-
614.
39. Lopez P, Gomez J, Mozo L, Gutierrez C, Suarez A: Cytokine
polymorphisms influence treatment outcomes in SLE
patients treated with antimalarial drugs. Arthritis Res Ther
2006, 8:R42. 
40. Freemer MM, King TE, Criswell LA: Association of smoking with
dsDNA autoantibody production in systemic lupus erythe-
matosus. Ann Rheumatic Dis 2006, 65:581-584.
41. Ghaussy NO, Sibbitt WL, Qualls CR: Cigarette smoking,
alcohol consumption, and the risk of systemic lupus erythe-
matosus: a case-control study. J Rheumatol 2001,  28:2449-
2453.
42. Majka DS, Holers VM: Cigarette smoking and the risk of sys-
temic lupus erythematosus and rheumatoid arthritis. Ann
Rheumatic Dis 2006, 65:561-563.
43. Mackay M, Stanevsky A, Wang T, Aranow C, Li M, Koenig S,
Ravetch JV, Diamond B: Selective dysregulation of the Fcγ γIIB
receptor on memory B cells in SLE. J Exp Med 2006,  203:
2157-2164.
44. Grootscholten C, Ligtenberg G, Hagen EC, van den Wall Bake
AW, de Glas-Vos JW, Bijl M, Assmann KJ, Bruijn JA, Weening JJ,
van Houwelingen HC, et al.: Azathioprine/methylprednisolone
versus cyclophosphamide in proliferative lupus nephritis. A
randomized controlled trial. Kidney Int 2006, 70:732-742.
45. Tseng CE, Buyon JP, Kim M, Belmont HM, Mackay M, Diamond B,
Marder G, Rosenthal P, Haines K, Ilie V, Abramson SB: The
effect of moderate-dose corticosteroids in preventing severe
flares in patients with serologically active, but clinically stable,
systemic lupus erythematosus – findings of a prospective,
randomized, double-blind, placebo-controlled trial. Arthritis
Rheum 2006, 54:3623-3632.
46. Fritsch-Stork R, Mullegger D, Skriner K, Jahn-Schmid B, Smolen
JS, Steiner G: The spliceosomal autoantigen heterogeneous
nuclear ribonucleoprotein A2 (hnRNP-A2) is a major T cell
autoantigen in patients with systemic lupus erythematosus.
Arthritis Res Ther 2006, 8:R118.
47. Kawamoto M, Harigai M, Hara M, Kawaguchi Y, Tezuka K, Tanaka
M, Sugiura T, Katsumata Y, Fukasawa C, Ichida H, : Expression
and function of inducible co-stimulator in patients with sys-
temic lupus erythematosus: possible involvement in exces-
sive interferon-γ γ and anti-double-stranded DNA antibody
production. Arthritis Res Ther 2006, 8:R62.
48. Hutloff A, Büchner K, Reiter K, Baelde HJ, Odendahl M, Jacobi A,
Dörner T, Kroczek RA: Involvement of inducible costimulator in
the exaggerated memory B cell and plasma cell generation in
systemic lupus erythematosus. Arthritis Rheum 2004,
50:3211-3220.
49. Iwai H, Abe M, Hirose S, Tsushima F, Tezuka K, Akiba H, Yagita
H, Okumura K, Kohsaka H, Miyasaka N, Azuma M: Involvement
of inducible costimulator-B7 homologous protein costimula-
tory pathway in murine lupus nephritis. J Immunol 2003, 171:
2848-2854.
50. Yurasov S, Tiller T, Tsuiji M, Velinzon K, Pascual V, Wardemann H,
Nussenzweig MC: Persistent expression of autoantibodies in
SLE patients in remission. J Exp Med 2006, 203:2255-2261.
51. de Leeuw K, Freire B, Srnit AJ, Bootsma H, Kallenberg CG, Bijl M:
Traditional and non-traditional risk factors contribute to the
development of accelerated atherosclerosis in patients with
systemic lupus erythematosus. Lupus 2006, 15:675-682.
52. Farzaneh-Far A, Roman MJ, Lockshin MD, Devereux RB, Paget
SA, Crow MK, Davis A, Sammaritano L, Levine DM, Salmon JE:
Impact of antiphospholipid antibodies on cardiovascular
disease in systemic lupus erythematosus. J Am Coll Cardiol
2006, 47:277A.
53. Binstadt BA, Patel PR, Alencar H, Nigrovic PA, Lee DM,
Mahmood U, Weissleder R, Mathis D, Benoist C: Particularities
of the vasculature can promote the organ specificity of
autoimmune attack. Nature Immunology 2006, 7:284-292.
54. Jackson M, Ahmad Y, Bruce IN, Coupes B, Brenchley PEC: Acti-
vation of transforming growth factor-β β1 and early atheroscle-
rosis in systemic lupus erythematosus. Arthritis Res Ther
2006, 8:R81.
55. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT,
Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB:
Mycophenolate mofetil or intravenous cyclophosphamide for
lupus nephritis. N Engl J Med 2005, 353:2219-2228.
56. Moore RA, Derry S: Systematic review and meta-analysis of
randomised trials and cohort studies of mycophenolate
mofetil in lupus nephritis. Arthritis Res Ther 2006, 8:R182.
57. Davidson A: New immune modulatory drugs for systemic
lupus erythematosus – what can we expect? Nat Clin Pract
Rheumatol 2006, 2:638-639.
58. Isenberg DA: B cell targeted therapies in autoimmune dis-
eases. J Rheumatol 2006, 33:24-28.
59. Dorner T, Lipsky PE: Signalling pathways in B cells: implica-
tions for autoimmunity. Curr Concepts Autoimmun Chron
Inflamm 2006, 305:213-240.
60. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern
WG, Lappin PB, Riccobene T, Abramian D, Sekut L, et al.: Gen-
eration and characterization of LymphoStat-B, a human mon-
oclonal antibody that antagonizes the bioactivities of B
lymphocyte stimulator. Arthritis Rheum 2003, 48:3253-3265.
61. Halpern WG, Lappin P, Zanardi T, Cai W, Corcoran M, Zhong J,
Baker KP: Chronic administration of belimumab, a BLyS
antagonist, decreases tissue and peripheral blood B-lympho-
cyte populations in cynomolgus monkeys: pharmacokinetic,
pharmacodynamic, and toxicologic effects. Toxicol Sci 2006,
91:586-599.
62. Ng KP, Leandro MJ, Edwards JC, Ehrenstein MR, Cambridge G,
Isenberg DA: Repeated B cell depletion in treatment of refrac-
tory systemic lupus erythematosus. Ann Rheumatic Dis 2006,
65:942-945.
63. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG,
Dörner T, Hiepe F: Competence and competition: the chal-
lenge of becoming a long-lived plasma cell. Nat Rev Immunol
2006, 6:741-750.
64. Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki
A, Moutsopoulos HM: Remission of proliferative lupus nephri-
tis following anti-B cell therapy is preceded by downregula-
tion of the T cell costimulatory molecule CD40-ligand. Arthritis
Rheum 2004, 50:S227.
65. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O,
Portales-Perez D, Abud-Mendoza C, Gonzalez-Amaro R: Clinical
and immunological effects of rituximab in patients with lupus
nephritis refractory to conventional therapy: a pilot study.
Arthritis Res Ther 2006, 8:R83.
66. Cambridge G, Leandro MJ, Teodorescu M, Manson J, Rahman A,
Isenberg DA, Edwards JC: B cell depletion therapy in systemic
lupus erythematosus – effect on autoantibody and antimicro-
bial antibody profiles. Arthritis Rheum 2006, 54:3612-3622.
67. Wallerskog T, Zhou W, Wohren-Herlenius M, Klareskog L, Malm-
strom V, Trollmo C: Increased Baff levels after rituximab-
induced B-cell depletion in SLE patients. Clin Immunol 2006,
119:S63.
68. Collins CE, Gavin AL, Migone TS, Hilbert DM, Nemazee D, Stohl
W:  B lymphocyte stimulator (BLyS) isoforms in systemic
lupus erythematosus: disease activity correlates better with
blood leukocyte BLyS mRNA levels than with plasma BLyS
protein levels. Arthritis Res Ther 2006, 8:R6.
Available online http://arthritis-research.com/content/9/4/215
Page 9 of 10
(page number not for citation purposes)69. FDA Public Health Advisory: life-threatening brain infection in
patients with systemic lupus erythematosus after Rituxan (ritux-
imab) treatment [www.fda.gov/cder/drug/advisory/rituximab.htm]
70. Dorner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM,
Burmester GR: Initial clinical trial of epratuzumab (humanized
anti-CD22 antibody) for immunotherapy of systemic lupus
erythematosus. Arthritis Res Ther 2006, 8:R74.
71. Stein R, Cardillo TM, Qu Z, Hansen HJ, Goldenberg DM: Anti-
lymphoma effects and mechanisms of action of epratuzumab
in cell lines and human xenografts. Cancer Biother Radiophar-
maceut 2006, 21:404-405.
72. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammari-
tano LR, Lockshin M, Merrill JT, Belmont HM, Askanase AD, et al. :
Combined oral contraceptives in women with systemic lupus
erythematosus. N Engl J Med 2005, 353:2550-2558.
73. Bootsma H, Spronk P, Derksen R, de Boer G, Wolters-Dicke H,
Hermans J, Limburg P, Gmelig-Meyling F, Kater L, Kallenberg C:
Prevention of relapses in systemic lupus-erythematosus.
Lancet 1995, 345:1595-1599.
74. Hiepe F, Manz RA, Radbruch A: The role of long-lived plasma
cells in autoimmunity. Ann Rheumatic Dis 2004, 63:16-17.
75. Hoyer BF, Manz RA, Radbruch A, Hiepe F: Impact of cellular
therapies on autoreactive, long-lived plasma cells in autoim-
mune diseases. Bone Marrow Transplant 2004, 33:S26.
76. Loh Y, Oyama Y, Statkute L, Quigley K, Yaung K, Gonda E, Barr
W, Jovanovic B, Craig R, Stefoski D, et al.: Development of a
secondary autoimmune disorder after hematopoeitic stem
cell transplantation for autoimmune diseases: role of condi-
tioning regimen used. Blood 2007, 109:2643-2548.
Arthritis Research & Therapy    Vol 9 No 4 Hansen et al.
Page 10 of 10
(page number not for citation purposes)